R. Thomas

555 total citations
23 papers, 442 citations indexed

About

R. Thomas is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R. Thomas has authored 23 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R. Thomas's work include Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). R. Thomas is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). R. Thomas collaborates with scholars based in Italy, United Kingdom and United States. R. Thomas's co-authors include Giuseppe D’Aiuto, Silvana Del Vecchio, Marco Salvatore, Maria Vincenza Carriero, Andrea Ciarmiello, Gerardo Botti, M. Brada, Nicholas D. James, S. Ashley and A. Gregor and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

R. Thomas

23 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Thomas Italy 10 196 162 134 112 88 23 442
Preeti K. Parhar United States 10 187 1.0× 147 0.9× 227 1.7× 81 0.7× 171 1.9× 24 572
José Alert Cuba 8 90 0.5× 76 0.5× 94 0.7× 92 0.8× 37 0.4× 23 272
B. Pellae-Cosset France 10 244 1.2× 53 0.3× 234 1.7× 69 0.6× 103 1.2× 21 488
Christoph Tinchon Austria 10 256 1.3× 66 0.4× 137 1.0× 45 0.4× 83 0.9× 26 480
Heikki Joensuu Finland 9 163 0.8× 234 1.4× 235 1.8× 23 0.2× 96 1.1× 11 551
A. Richetti Switzerland 13 178 0.9× 120 0.7× 253 1.9× 35 0.3× 126 1.4× 40 569
Michelle Echevarria United States 9 253 1.3× 77 0.5× 252 1.9× 44 0.4× 89 1.0× 30 561
A.N. Harnett United Kingdom 12 241 1.2× 73 0.5× 69 0.5× 22 0.2× 105 1.2× 31 486
W. Alberti Germany 10 129 0.7× 122 0.8× 146 1.1× 32 0.3× 46 0.5× 32 443
T.B. Johannesen Norway 11 142 0.7× 29 0.2× 111 0.8× 71 0.6× 51 0.6× 17 472

Countries citing papers authored by R. Thomas

Since Specialization
Citations

This map shows the geographic impact of R. Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Thomas more than expected).

Fields of papers citing papers by R. Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Thomas. The network helps show where R. Thomas may publish in the future.

Co-authorship network of co-authors of R. Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of R. Thomas. A scholar is included among the top collaborators of R. Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Thomas. R. Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peterson, J.R., et al.. (2019). Abstract PD6-12: Evaluating racial disparities in breast cancer referrals for hereditary risk assessment. Cancer Research. 79(4_Supplement). PD6–12. 1 indexed citations
2.
3.
Frasci, G., P. Comella, R. Thomas, et al.. (2005). A two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration is highly effective in large operable breast cancer. Final analysis of a SICOG phase II study. Journal of Clinical Oncology. 23(16_suppl). 566–566. 4 indexed citations
4.
D’Aiuto, Giuseppe, P. Comella, R. Thomas, et al.. (2005). A 2-month cisplatin–epirubicin–paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study. Annals of Oncology. 16(8). 1268–1275. 9 indexed citations
5.
Frasci, G., P. Comella, Andrea Siani, et al.. (2005). Weekly cisplatin-epirubicin-paclitaxel with G-CSF support (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Final results of the 9908 SICOG trial. Journal of Clinical Oncology. 23(16_suppl). 580–580. 3 indexed citations
6.
7.
Frasci, G., P. Comella, R. Thomas, et al.. (2004). Two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study. Journal of Clinical Oncology. 22(14_suppl). 601–601. 1 indexed citations
8.
Comella, G., P. Comella, R. Thomas, et al.. (2004). Comparison of weekly cisplatin-epirubicin-paclitaxel (PET) with triweekly epirubicin-paclitaxel (ET) in locally advanced breast cancer (LABC). SICOG 9908 phase III tria. Journal of Clinical Oncology. 22(14_suppl). 511–511. 3 indexed citations
9.
Thomas, R., et al.. (2001). Immunohistochemical reactivity of anti-melanoma monoclonal antibody 225.28S in human breast cancer biopsies.. PubMed. 21(2A). 925–30. 5 indexed citations
10.
Hammami, Mouhanad, et al.. (2001). Regional Bone Mass Measurement from Whole-Body Dual Energy X-Ray Absorptiometry Scan. Journal of Clinical Densitometry. 4(2). 131–136. 12 indexed citations
11.
Frasci, G., Giuseppe D’Aiuto, R. Thomas, et al.. (2000). Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study. Annals of Oncology. 11(3). 367–372. 31 indexed citations
12.
Frasci, G., P. Comella, Anna Apicella, et al.. (1999). Cisplatin — epirubicin — paclitaxel (PET) weekly administration with G-CSF support in advanced breast cancer (ABC). A phase II study. European Journal of Cancer. 35. S318–S318. 1 indexed citations
13.
Lastoria, Secondo, et al.. (1998). Scintimammography with 99mTc-MDP: experience of the National Cancer Institute of Naples. European Journal of Radiology. 27. S275–S281. 4 indexed citations
14.
Ciarmiello, Andrea, Silvana Del Vecchio, Maria Vincenza Carriero, et al.. (1998). Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.. Journal of Clinical Oncology. 16(5). 1677–1683. 111 indexed citations
15.
Thomas, R., Immacolata Capasso, A. De Matteis, et al.. (1998). Long term survival in elderly breast cancer patients treated with tamoxifen (TAM) alone vs surgery followed by TAM. European Journal of Cancer. 34. S126–S126. 1 indexed citations
16.
Brazil, L., R. Thomas, Robert Laing, et al.. (1997). Verbally administered Barthel Index as functional assessment in brain tumour patients. Journal of Neuro-Oncology. 34(2). 187–192. 36 indexed citations
17.
Vecchio, Silvana Del, Andrea Ciarmiello, Leonardo Pace, et al.. (1997). Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.. PubMed. 38(9). 1348–51. 81 indexed citations
18.
Thomas, R., et al.. (1996). An analysis of surveillance for stage I combined teratoma - seminoma of the testis. British Journal of Cancer. 74(1). 59–62. 8 indexed citations
19.
Thomas, R., et al.. (1995). Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Medical dosimetry. 20(1). 69–69. 2 indexed citations
20.
Thomas, R., et al.. (1994). Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiotherapy and Oncology. 33(2). 113–116. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Preeti K. Parhar Breakdown of academic impact, for papers by José Alert Breakdown of academic impact, for papers by B. Pellae-Cosset Breakdown of academic impact, for papers by Christoph Tinchon Breakdown of academic impact, for papers by Heikki Joensuu Breakdown of academic impact, for papers by A. Richetti Breakdown of academic impact, for papers by Michelle Echevarria Breakdown of academic impact, for papers by A.N. Harnett Breakdown of academic impact, for papers by W. Alberti Breakdown of academic impact, for papers by T.B. Johannesen
Rankless by CCL
2026